Osteoking prevents bone loss and enhances osteoblastic bone formation by modulating the AGEs/IGF‐1/β‐catenin/OPG pathway in type 2 diabetic db/db mice DOI
Yi Yang, Rong Li, Peijin Wang

et al.

Cell Biology International, Journal Year: 2024, Volume and Issue: 48(10), P. 1507 - 1519

Published: June 27, 2024

Abstract Type 2 diabetic osteoporosis (T2DOP) is a skeletal metabolic syndrome characterized by impaired bone remodeling due to type diabetes mellitus, and there are drawbacks in the present treatment. Osteoking (OK) widely used for treating fractures femoral head necrosis. However, OK seldom reported field of T2DOP, its role mechanism action need be elucidated. Consequently, this study investigated whether improves mechanisms diabetes‐induced injury. We db/db mice as T2DOP model stimulated MC3T3‐E1 cells (osteoblast cell line) with high glucose (HG, 50 mM) advanced glycation end products (AGEs, 100 µg/mL), respectively. The effect on was assessed using combined 3‐point mechanical bending test, hematoxylin eosin staining, enzyme‐linked immunosorbent assay. enhancing differentiation mineralization under HG AGEs conditions an alkaline phosphatase activity assay alizarin red S staining. AGEs/insulin‐like growth factor‐1(IGF‐1)/β‐catenin/osteoprotegerin (OPG) pathway‐associated protein levels were assayed western blot analysis immunohistochemical found that reduced hyperglycemia, attenuated damage, repaired remodeling, increased tibial IGF‐1, β‐catenin, OPG expression, decreased receptor activator nuclear kappa B ligand expression mice. Moreover, promoted conditions, respectively, regulated AGEs/IGF‐1/β‐catenin/OPG proteins. In conclusion, our results suggest may lower blood glucose, alleviate attenuate part through activation pathway.

Language: Английский

Biomarkers That Seem to Have the Greatest Impact on Promoting the Formation of Atherosclerotic Plaque in Current Scientific Research DOI Creative Commons

Maksymilian Kłosowicz,

Dawid Leksa,

Dorota Bartusik‐Aebisher

et al.

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 46(9), P. 9503 - 9522

Published: Aug. 29, 2024

Atherosclerosis is a chronic inflammatory disease that causes degenerative and productive changes in the arteries. The resulting atherosclerotic plaques restrict vessel lumen, causing blood flow disturbances. Plaques are formed mainly large- medium-sized arteries, usually at bends forks where there turbulence flow. Depending on their location, they can lead to various states such as myocardial infarction, stroke, renal failure, peripheral vascular diseases, or sudden cardiac death. In this work, we reviewed literature early detection of atherosclerosis markers application photodynamic therapy atherosclerosis-related diseases. Herein, described roles C-reactive protein, insulin, osteopontin, osteoprotegerin, copeptin, TGF-β cytokine family, amino acid homocysteine. Also, discuss role microelements iron, copper, zinc, Vitamin D promoting formation plaque. Dysregulation administered compounds associated with an increased risk atherosclerosis. Additionally, taking into account pathophysiology plaque formation, believe maintaining homeostasis range biomarkers mentioned article crucial for slowing down process development stability already formed.

Language: Английский

Citations

5
Cardiometabolic Effects of Denosumab in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression: RCT DOI Creative Commons
Sabashini K. Ramchand, Rudolf Hoermann, Shane White

et al.

The Journal of Clinical Endocrinology & Metabolism, Journal Year: 2024, Volume and Issue: 109(10), P. e1857 - e1866

Published: Jan. 4, 2024

Abstract Context Menopause is associated with changes in musculoskeletal, body composition, and metabolic parameters that may be amplified premenopausal women receiving estradiol suppression for breast cancer. Denosumab offsets deleterious skeletal effects of has been reported to have on composition preclinical observational studies, but evidence from double-blind randomized controlled trials limited. Objective To assess the effect denosumab parameters. Methods In a prespecified secondary analysis 12-month randomized, double-blind, placebo-controlled trial, 68 cancer initiating ovarian function aromatase inhibition were 60-mg or placebo administered at baseline 6 months. Outcome measures total regional fat lean mass (DXA), index (BMI), waist hip circumference, fasting glucose, HOMA-IR, lipid profile. Using mixed model, between-group mean adjusted differences over time are reported. Results Over 12 months, relative placebo, android gynoid decreased group (−266 g [95% CI −453 −79], P = .02, −452 [−783 −122], .03, respectively). Total circumference lower not significantly (−1792 [−3346 −240], .08 (− 3.77 cm [−6.76 −0.79], .06, No significant treatment detected mass, BMI, Conclusion suppression, decreases some no detectable other

Language: Английский

Citations

4
Osteokines in Nonalcoholic Fatty Liver Disease DOI
Ilias D. Vachliotis, Athanasios D. Anastasilakis, Vasileios Rafailidis

et al.

Current Obesity Reports, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 3, 2024

Language: Английский

Citations

4
Unraveling the link between metabolic dysfunction-associated steatotic liver disease and osteoporosis: a bridging function of gut microbiota DOI Creative Commons
Jing Zhang, Zhen Sun,

Lili Xu

et al.

Frontiers in Endocrinology, Journal Year: 2025, Volume and Issue: 16

Published: April 1, 2025

This review examines the strong association between metabolic dysfunction-associated steatotic liver disease (MASLD) and osteoporosis (OP), with a particular focus on role of gut microbiota in linking these two disorders. Both MASLD OP are closely linked to syndrome, their pathogenesis involves multiple factors, such as inflammatory response, insulin resistance, altered intestinal permeability, estrogen deficiency. Dysregulation not only affects hepatic fat accumulation bone metabolism disorders through metabolites, short-chain fatty acids, but also exacerbates systemic chronic inflammation by impairing barrier function, thus accelerating progression both diseases. article summarizes recent studies that highlight central co-morbid factor OP, offering new perspectives for future diagnostic therapeutic strategies.

Language: Английский

Citations

0
RNA interference-mediated osteoprotegerin silencing increases the receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio and promotes osteoclastogenesis DOI
Shu‐Chen Wei,

Hui-Hong Chen,

Liu-Rong Xie

et al.

World Journal of Stem Cells, Journal Year: 2025, Volume and Issue: 17(4)

Published: April 21, 2025

In vivo degradation of bone scaffolds is significantly influenced by osteoclast (OC) activity, which orchestrated the interplay between receptor activator nuclear factor-kappa B ligand (RANKL) and osteoprotegerin (OPG). The ratio RANKL/OPG a crucial determinant OC-mediated resorption, plays an integral role in remodeling scaffold degradation. Elevated levels RANKL relative to OPG enhance osteoclastogenesis, thereby accelerating process essential for integrating into host tissue. To elucidate effects gene silencing on osteoclastogenesis within rat marrow-derived mesenchymal stem cells (BMSCs). By investigating these effects, study aimed provide deeper insights regulatory mechanisms that influence degradation, potentially leading improved repair regeneration strategies. We employed recombinant lentiviral plasmids silence BMSCs achieve aims. efficacy was assessed using quantitative reverse transcription polymerase chain reaction western blot analysis measure expression RANKL. Tartrate-resistant acid phosphatase staining utilized evaluate formation OCs. Additionally, co-immunoprecipitation assays were conducted explore interactions proteins, further assessing biochemical pathways involved osteoclastogenesis. resulted significant increase ratio, evidenced decreased increased Enhanced observed through tartrate-resistant staining, indicated substantial rise OC response altered balance. provided concrete evidence direct interaction substantiating their pivotal roles regulating activity. findings from this underscore critical axis Silencing effectively increases promoting activity enhancing This mechanism offers promising avenue modulating processes, effective successful integration damaged sites. Future research might focus optimizing control better facilitate tissue engineering regenerative therapies.

Language: Английский

Citations

0
Anti-osteoporotic treatments in the era of non-alcoholic fatty liver disease: friend or foe DOI Creative Commons
Maria Chondrogianni, Ioannis Kyrou, Θεόδωρος Ανδρουτσάκος

et al.

Frontiers in Endocrinology, Journal Year: 2024, Volume and Issue: 15

Published: March 8, 2024

Over the last years non-alcoholic fatty liver disease (NAFLD) has grown into most common chronic globally, affecting 17-38% of general population and 50-75% patients with obesity and/or type 2 diabetes mellitus (T2DM). NAFLD encompasses a spectrum diseases, ranging from simple steatosis (non-alcoholic liver, NAFL) steatohepatitis (NASH; or metabolic dysfunction-associated steatohepatitis, MASH) to fibrosis cirrhosis failure or/and hepatocellular carcinoma. Due its increasing prevalence associated morbidity mortality, disease-related broader socioeconomic burden is substantial. Of note, currently there no globally approved pharmacotherapy for NAFLD. Similar NAFLD, osteoporosis constitutes also silent disease, until an osteoporotic fracture occurs, which poses markedly significant burden. Increasing emerging data have recently highlighted links between osteoporosis, linking pathogenesis process bone remodeling. However, clinical studies are still limited demonstrating this associative relationship, while more evidence needed towards discovering potential causative links. Since these two diseases frequently co-exist, suggesting that anti-osteoporosis treatments may affect progression by impacting on pathogenetic mechanisms. In present review, we overview current understanding liver-bone cross talk summarize experimental correlating focusing possible effects anti-osteoporotic drugs

Language: Английский

Citations

3
Extra-osseous Roles of the RANK-RANKL-OPG Axis with a Focus on Skeletal Muscle DOI Creative Commons
John Gostage, Paul J. Kostenuik, Katarzyna Goljanek‐Whysall

et al.

Current Osteoporosis Reports, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 26, 2024

Language: Английский

Citations

3
RANK–RANKL–OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives DOI Open Access
Federico Monti, Federica Perazza, Laura Leoni

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(17), P. 9193 - 9193

Published: Aug. 24, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD)—and its worse form, metabolic-associated steatohepatitis (MASH), characterised by inflammation and damage—corresponds to the liver’s involvement in metabolic syndrome, which constitutes an economic burden for healthcare systems. However, biomolecular pathways that contribute are not completely clear. Abnormalities of bone metabolism frequent people affected disease, with reduced density increased risk fracture. Receptor activator NF-κB (RANK), receptor ligand (RANKL), osteoprotegerin(OPG) critical regulators metabolism, performing pleiotropic effects, may have potential disorders like MASLD, resulting a topic great interest intrigue. This narrative review aims investigate this role implications MASLD development progression hepatocellular carcinoma, represents worst complication.

Language: Английский

Citations

2
Osteoprotegerin mediates adipogenesis in obesity DOI Creative Commons
Zipan Lyu,

Yau-Tuen Chan,

Yuanjun Lu

et al.

Journal of Advanced Research, Journal Year: 2024, Volume and Issue: 62, P. 245 - 255

Published: June 19, 2024

Adipogenesis, the process of white adipose tissue expansion, plays a critical role in development obesity. Osteoprotegerin (OPG), known for its bone metabolism regulation, emerges as potential regulator mediating adipogenesis during obesity onset. This study aims to elucidate involvement OPG early phases diet-induced and explore therapeutic management. Using model, we investigated expression patterns adipocytes explored mechanisms underlying adipogenesis. We also assessed effects targeted silencing recombinant administration on progression insulin resistance. Additionally, impact electroacupuncture treatment levels management was evaluated both animal models human participants. prominently activated tissues phase Hyperlipidemia induced Cbfa1-dependent transcription, initiating promoting adipogenesis, leading cell-size expansion lipid storage. Intracellular physically bound RAR released PPARɤ/RXR complex, activating adipogenesis-associated gene expression. Targeted suppressed development, while promoted disease resistance obese mice. Electroacupuncture an OPG-dependent manner improved parameters key development. Targeting holds promise prevention obesity, evidenced by efficacy modulating managing obesity-related outcomes.

Language: Английский

Citations

1
Correlation of metabolic markers and OPG gene mutations with bone mass abnormalities in postmenopausal women DOI Creative Commons
Jun Li, Zixin Li, Siyuan Li

et al.

Journal of Orthopaedic Surgery and Research, Journal Year: 2024, Volume and Issue: 19(1)

Published: Nov. 1, 2024

The aim was to investigate the relationship between metabolic indices and abnormal bone mass (ABM), analyse association osteoprotegerin (OPG) gene mutations ABM, explore interaction effect of type 2 diabetes mellitus (T2DM) OPG on mineral density (BMD) in postmenopausal women provide a new supplementary index reliable basis for early identification osteoporosis (OP) clinical setting.

Language: Английский

Citations

1